{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:56:03Z","timestamp":1771016163060,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":6392,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1989,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Concurrent with a phase\u2010II trial of 4HPR in patients with various cancers, we studied the plasma pharmacokinetics of both 4HPR and its major metabolite 4MPR as well as the effect of 4HPR administration on plasma retinol concentrations using a simple, specific and sensitive HPLC procedure. Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg\/m<jats:sup>2<\/jats:sup>) in 3 cancer patients were the following: 4HPR, t<jats:sup>\u03b2<\/jats:sup><jats:sub>1\/2<\/jats:sub> = 13.7 hr, AUC = 3.49 \u03bcg.hr\/ml, CL = 56.57 L\/hr\/m<jats:sup>2<\/jats:sup>; 4MPR, t<jats:sup>\u03b2<\/jats:sup><jats:sub>1\/2<\/jats:sub> = 23.0 hr, AUC = 1.15 \u03bcg.hr\/ml, CL = 239.29 L\/hr\/m<jats:sup>2<\/jats:sup>. We also found that oral administration of 4HPR resulted in a rapid, profound and significant reduction in plasma retinol concentrations. The mean plasma retinol concentrations for 9 patients decreased 60% from baseline to below 200 ng\/ml within 1\u20132 weeks of 4HPR dosing initiation. In addition, there was a concurrent, significant reduction in plasma retinol\u2010binding protein levels in these patients. The mechanism whereby 4HPR reduces plasma retinol levels <jats:italic>in vivo<\/jats:italic> has not been determined. The addition of 4HPR to pooled human plasma at 37\u00b0C <jats:italic>in vitro<\/jats:italic> did not reduce endogenous retinol levels, suggesting no direct chemical interaction between these 2 retinoids.<\/jats:p>","DOI":"10.1002\/ijc.2910430106","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T21:12:56Z","timestamp":1171919576000},"page":"22-26","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacokinetics of n\u20104\u2010hydroxyphenyl\u2010retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients"],"prefix":"10.1002","volume":"43","author":[{"given":"Yei\u2010Mei","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min\u2010Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"JR.","given":"Frank L.","family":"Meyskens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb12733.x"},{"key":"e_1_2_1_3_1","first-page":"42","volume-title":"The retinoids","author":"Goodman D. S.","year":"1985"},{"key":"e_1_2_1_4_1","first-page":"7","volume-title":"The retinoids","author":"Goodman D. S.","year":"1985"},{"key":"e_1_2_1_5_1","first-page":"1125","article-title":"Plasma kinetics of oral retinol in cancer patients","volume":"68","author":"Goodman G. E.","year":"1984","journal-title":"Cancer. Treat. Rep."},{"key":"e_1_2_1_6_1","first-page":"1359","article-title":"Comparative subacute toxicity of retinyl acetate and three synthetic retinamides in Swiss mice","volume":"63","author":"Hixson E. J.","year":"1979","journal-title":"J. nat. Cancer Inst."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0019-2791(65)90004-2"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01922901"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910320306"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/3.12.1469"},{"key":"e_1_2_1_11_1","first-page":"2469","article-title":"Inhibition of carcinogenesis by retinoids","volume":"43","author":"Moon R. C.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470720943.ch10"},{"key":"e_1_2_1_13_1","first-page":"1339","article-title":"N\u2010(4\u2010Hydroxyphenyl)\u2010Retinamide, a new retinoid for prevention of breast cancer in the rat","volume":"39","author":"Moon R. C.","year":"1979","journal-title":"Cancer Res."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1967)20:5<857::AID-CNCR2820200545>3.0.CO;2-3"},{"key":"e_1_2_1_15_1","unstructured":"SAS Institute IncSAS user's guide: statistics5th edition Cary NC (1985)."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600650713"},{"key":"e_1_2_1_17_1","first-page":"2528","article-title":"Chemoprevention of cancer with retinoids","volume":"38","author":"Sporn M. B.","year":"1978","journal-title":"Fed. Proc."},{"key":"e_1_2_1_18_1","first-page":"632","article-title":"Bio\u2010Transformation and biological activity of N\u2010(4\u2010Hydroxyphenyl)\u2010Retinamide derivatives in rodents","volume":"219","author":"Swanson B. N.","year":"1981","journal-title":"J. pharmacol. exp. Ther."},{"key":"e_1_2_1_19_1","first-page":"168","article-title":"Pharmacokinetics of N\u2010(4\u2010Hydroxyphenyl)\u2010All\u2010Trans\u2010Retinamide in rats","volume":"8","author":"Swanson B. N.","year":"1980","journal-title":"Drug. Metab. Disp."},{"key":"e_1_2_1_20_1","first-page":"1647","article-title":"Inhibition of growth and regression of a transplantable rat chondrosarcoma by three retinoids","volume":"60","author":"Trown R. W.","year":"1976","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_21_1","first-page":"304","volume-title":"The retinoids","author":"Underwood B. A.","year":"1985"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910430106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910430106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T03:05:12Z","timestamp":1697943912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910430106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1989,1,15]]}},"alternative-id":["10.1002\/ijc.2910430106"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910430106","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1,15]]}}}